Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

The RNA binding protein ZFP36L2 displays tissue-selective mRNA targeting in mice

Stephenson GS., Fleifel D., Cook JG., Laederach A., Ramos SBV.

Animal Study on Systemic / IV, published in RNA Biol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
RNA Biol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42319349
PMCID
PMC13290092
DOI
10.1080/15476286.2026.2690792

Abstract (original English)

ZFP36L2 (zinc finger protein 36 like 2, C3H type-ZFP) is an RNA-binding protein targeting transcripts rich in adenine-uridine elements (AREs). Previous transcriptomic analysis suggested that ZFP36L2 displays a distinct transcript preference or 'specific activity'. However, this analysis was restricted to a few tissues. Here, using experimental data in multiple tissues we detected a remarkable transcript selectivity depending on the tissue. Given that ZFP36L2 accelerates the degradation of specific ARE-transcripts upon binding, we obtained differential expression transcriptomic data on a Zfp36l2 knock-out mouse model to delve into the mechanisms governing this tissue-specific targeting. Transcriptomic analyzes of up-regulated ARE-transcripts in six tissues, lung, liver, bone marrow, spleen, kidney, and ovary of the Zfp36l2-deficient mouse confirmed that there is high tissue preference in ZFP36L2 targets. We observed only one common up-regulated gene, Apol11b, among these six different tissues. However, we do observe common trends, specifically an enrichment in protein coding genes in the up-regulated genes, consistent with these RBP primarily targeting genes on their 3' UTRs. Interestingly, we observed a significant increase in the proportion of IgV (immunoglobulin) genes being up-regulated. We further performed eCLIP (Enhanced Cross-Linking&ImmunoPreciptation) on a mouse cell l

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMice, KnockoutMiceRNA-Binding ProteinsRNA, Messenger3' Untranslated RegionsGene Expression ProfilingOrgan SpecificityGene Expression RegulationBinding Sites

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research